Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 23, 2015, Pages 7267-7272

  Yosef, Ido ^a   Manor, Miriam ^a   Kiro, Ruth ^a   Qimron, Udi ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

CRISPR Cas; Ex vivo treatment; Lysogenization; Positive selection

Indexed keywords

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENOME; BACTERICIDAL ACTIVITY; BACTERIOPHAGE; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CRISPR CAS SYSTEM; LYSOGENIZATION; NONHUMAN; PLASMID; PRIORITY JOURNAL; SENSITIZATION; BACTERIUM; GENETICS; PHYSIOLOGY; VIROLOGY;

BACTERIA; BACTERIOPHAGES; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; DRUG RESISTANCE, BACTERIAL; LYSOGENY; PLASMIDS;

EID: 84931291929     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1500107112     Document Type: Article

References (33)

1. Marraffini LA, Sontheimer EJ (2010) CRISPR interference: RNA-directed adaptive immunity in bacteria and archaea. Nat Rev Genet 11(3):181-190.
2. Barrangou R, et al. (2007) CRISPR provides acquired resistance against viruses in prokaryotes. Science 315(5819):1709-1712.
3. Hale CR, et al. (2009) RNA-guided RNA cleavage by a CRISPR RNA-Cas protein complex. Cell 139(5):945-956.
4. Cong L, et al. (2013) Multiplex genome engineering using CRISPR/Cas systems. Science 339(6121):819-823.
5. Mali P, et al. (2013) RNA-guided human genome engineering via Cas9. Science 339(6121):823-826.
6. Niu Y, et al. (2014) Generation of gene-modified cynomolgus monkey via Cas9/RNAmediated gene targeting in one-cell embryos. Cell 156(4):836-843.
7. Jiang W, Bikard D, Cox D, Zhang F, Marraffini LA (2013) RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nat Biotechnol 31(3):233-239.
8. Qi LS, et al. (2013) Repurposing CRISPR as an RNA-guided platform for sequence specific control of gene expression. Cell 152(5):1173-1183.
9. Gilbert LA, et al. (2013) CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 154(2):442-451.
10. O'Connell MR, et al. (2014) Programmable RNA recognition and cleavage by CRISPR/ Cas9. Nature 516(7530):263-266.
11. Yin H, et al. (2014) Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol 32(6):551-553.
12. Hale CR, et al. (2012) Essential features and rational design of CRISPR RNAs that function with the Cas RAMP module complex to cleave RNAs. Mol Cell 45(3):292-302.
13. Gomaa AA, et al. (2014) Programmable removal of bacterial strains by use of genome-targeting CRISPR-Cas systems. MBio 5(1):e00928-e13.
14. Bikard D, Hatoum-Aslan A, Mucida D, Marraffini LA (2012) CRISPR interference can prevent natural transformation and virulence acquisition during in vivo bacterial infection. Cell Host Microbe 12(2):177-186.
15. Garneau JE, et al. (2010) The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature 468(7320):67-71.
16. Citorik RJ, Mimee M, Lu TK (2014) Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. Nat Biotechnol 32(11):1141-1145.
17. Bikard D, et al. (2014) Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nat Biotechnol 32(11):1146-1150.
18. Yosef I, Kiro R, Molshanski-Mor S, Edgar R, Qimron U (2014) Different approaches for using bacteriophages against antibiotic-resistant bacteria. Bacteriophage 4(1):e28491.
19. Brouns SJ, et al. (2008) Small CRISPR RNAs guide antiviral defense in prokaryotes. Science 321(5891):960-964.
20. Edgar R, Friedman N, Molshanski-Mor S, Qimron U (2012) Reversing bacterial resistance to antibiotics by phage-mediated delivery of dominant sensitive genes. Appl Environ Microbiol 78(3):744-751.
21. Lech K, Brent R, Irwin N (2001) Lambda as a cloning vector. Curr Protoc Mol Biol, Chap 1, Unit 1.10.
22. Bush K, Fisher JF (2011) Epidemiological expansion, structural studies, and clinical challenges of new β-lactamases from gram-negative bacteria. Annu Rev Microbiol 65: 455-478.
23. Chen J, Novick RP (2009) Phage-mediated intergeneric transfer of toxin genes. Science 323(5910):139-141.
24. Tamulaitis G, et al. (2014) Programmable RNA shredding by the type III-A CRISPR-Cas system of Streptococcus thermophilus. Mol Cell 56(4):506-517.
25. Staals RH, et al. (2014) RNA targeting by the type III-A CRISPR-Cas Csm complex of Thermus thermophilus. Mol Cell 56(4):518-530.
26. Edgar R, Qimron U (2010) The Escherichia coli CRISPR system protects from λ lysogenization, lysogens, and prophage induction. J Bacteriol 192(23):6291-6294.
27. Merril CR, Scholl D, Adhya SL (2003) The prospect for bacteriophage therapy in Western medicine. Nat Rev Drug Discov 2(6):489-497.
28. Qimron U, Marintcheva B, Tabor S, Richardson CC (2006) Genomewide screens for Escherichia coli genes affecting growth of T7 bacteriophage. Proc Natl Acad Sci USA 103(50):19039-19044.
29. Lang LH (2006) FDA approves use of bacteriophages to be added to meat and poultry products. Gastroenterology 131(5):1370.
30. Abuladze T, et al. (2008) Bacteriophages reduce experimental contamination of hard surfaces, tomato, spinach, broccoli, and ground beef by Escherichia coli O157:H7. Appl Environ Microbiol 74(20):6230-6238.
31. Wirtanen G, Salo S, Helander IM, Mattila-Sandholm T (2001) Microbiological methods for testing disinfectant efficiency on Pseudomonas biofilm. Colloids Surf B Biointerfaces 20(1):37-50.
32. Pendleton JN, Gorman SP, Gilmore BF (2013) Clinical relevance of the ESKAPE pathogens. Expert Rev Anti Infect Ther 11(3):297-308.
33. Boucher HW, et al. (2009) Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48(1):1-12.